MiMedx Group, Inc.
| Nasdaq: MDXG
MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.